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5-En-androstene-3p,17p-diol inhibits the growth of MCF-7 breast cancer
cells when oestrogen receptors are blocked by oestradiol
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Department of Clinical Pathophysiology, University of Turin, Via Genova 3, 10126 Turin, Italy.
Summary Adrenal androgens show a dual and apparently opposite effect on the growth of oestrogen-
responsive breast cancer: they stimulate growth on their own, but counteract the growth-stimulatory effect of
oestrogens. Focusing on the inhibitory action we have studied the effects of 5-en-androstene-3p,17p-diol
(ADIOL) on the growth of oestrogen-responsive MCF-7 breast cancer cells in the presence of oestrogens
(oestradiol and diethylstilboestrol), antiestrogens (tamoxifen) and antiandrogens (hydroxyflutamide). The
inhibition of oestrogen-stimulated growth, attained with nanomolar concentrations of ADIOL, was not
modified by increasing concentrations of diethylstilboestrol up to 100 nm. This inhibition was counteracted by
antiandrogens, which were unable to block the ADIOL stimulatory effect in steroid-free medium. On the other
hand, in the presence of tamoxifen ADIOL showed an additive antiproliferative activity also in steroid-free
medium, rather than the usual stimulatory effect. These results suggest that ADIOL stimulates breast cancer
cell growth via oestrogen receptors, but inhibits oestrogen-stimulated growth via androgen receptors.
Adrenal androgens, including dehydroepiandrosterone
(DHEA), dehydroepiandrosterone sulphate (DHEAS) and 5-
en-androstene-3p,17p-diol (ADIOL), are the major secretory
products of the adrenal gland. However, their physiological
role is still unknown. Epidemiological and experimental
studies suggest that they might affect the growth of human
breast tumours (Bulbrook et al., 1971; Wang et al., 1975;
Segaloff et al., 1980; Zumoff et al., 1981; Helzlsouer et al.,
1992). In vitro studies showed that they may exert a dual and
opposite effect on the growth of breast cancer cells (Adams et
al., 1981; Poulin & Labrie, 1986; Najid & Habrioux, 1990;
Boccuzzi et al., 1992a). ADIOL is able to stimulate the in
vitro growth of oestrogen-dependent breast cancer cell lines
in steroid-free medium when added at the concentrations
found in the plasma of post-menopausal women (Nahoul et
al., 1985). Moreover, it is coupled with the transcriptional
activation of proteins which are markers of oestrogenic
action (Adams et al., 1981; Poulin & Labrie, 1986). The
growth-stimulatory activity of ADIOL depends on its direct
binding to oestrogen receptors (ERs) (Poortman et al., 1975;
Kreitman & Bayard, 1979; Adams et al., 1980; Rochefort &
Garcia, 1984), without any involvement of the aromatase
pathway (Najid, 1991; Pizzini et al., 1992). On the other
hand, we have recently shown that ADIOL inhibits the
oestradiol-induced growth of human breast cancer cells (Boc-
cuzzi et al., 1992a). The mechanism of this antiproliferative
action has not yet been clarified. As ADIOL binds to ERs, it
might partially displace oestradiol (E2) from its own receptors
(Thjissen et al., 1975; Garcia & Rochefort, 1978; Nicholson
et al., 1978). Alternatively, since ADIOL binds also androgen
receptors (ARs) (Poortman et al., 1975) and exerts full
androgenic activity (Rosenfield & Otto, 1972; Demish et al.,
1973; Hackemberg et al., 1993), it might inhibit growth via
ARs.
To clarify the mechanisms of the ADIOL antiproliferative
action, i.e. to differentiate between an ER- and AR-mediated
activity, we evaluated its effects on the growth of the
hormone-responsive MCF-7 breast cancer cells in presence of
the antioestrogen tamoxifen (TAM), of the antiandrogen
hydroxyflutamide (OH-FLU) and of the non-steroidal oestro-
gen diethylstilboestrol (DES). Data indicate that AR activa-
tion is involved in the antiproliferative action of ADIOL.
This offers an experimental background for the suggestion
that a combined hormonal therapy approach might be
superior to TAM alone in the post-menopausal breast
cancer.
Materials and methods
Chemicals
ADIOL, E2, dihydrotestosterone (DHT), TAM and DES
were purchased from Sigma (USA). OH-FLU was from
Schering Plough (USA). The compounds were diluted in
ethanol; the final concentration of ethanol in the medium did
not exceed 0.1%, which had no detectable effect on cell
growth. However, ethanol at the same concentration was also
added to the medium of control cultures. Fetal calf serum
(FCS) (Eurobio, France) was treated with charcoal dextran
(10:1) to remove steroids; the extraction was carried out at
25°C for 60 min.
Cell culture
The MCF-7 cell line was from the American Type Culture
Collection (USA). Cells were cultured in 25 cm2 plastic flasks
(Falcon, USA) in RPMI-1640 phenol red-free medium
(Gibco, UK), supplemented with 2mM L-glutamine (Euro-
bio, France), 100 IU ml-' penicillin G, 100 fig ml-' strep-
tomycin and with 10% FCS added. The cells were grown in a
humidified atmosphere containing 5% (v/v) carbon dioxide
at 37'C. The medium was changed every 2 days. The cells
were passaged weekly by trypsin 0.05% and EDTA
0.02%.
Cellproliferation experiments in culture
Approximately 2 x 104cells per well were plated in 24-well
culture plates (Falcon, USA). Cells were allowed to attach
for 24 h in the medium supplemented with 10% steroid-
stripped FCS. Then the seeding medium was replaced with
one containing hormones (for details about media see the
figure legends). The medium was renewed on the fourth day.
Cells were harvested by trypsin at the established time and
counted (twice for each well) using a Burker chamber. Statis-
tical evaluation was carried out on paired data using Student's
t-test.
Results
Effect ofADIOL and DHT on E2-inducedgrowth ofMCF-7
cells
In steroid-free medium, MCF-7 cell growth is stimulated by
ADIOL at concentrations between 2 and 200 nM (Figures 1
and 2). DHT has a biphasic effect on cell proliferation
(Figure 2): concentrations up to 20 nM inhibit cell growth,
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Figure 1 Effects of E2, ADIOL and TAM on the growth of
MCF-7 cells. Cells, were seeded at a density of about
2 x 10'cells per dish and cultured in a medium supplemented
with 10% steroid-stripped fetal calf serum (FCS-DCC). One day
after seeding, the cells were divided into eight groups. One group
was continued in FCS-DCC (control); the others were supple-
mented with 1 nm E2, 1 nM E2+ 2 nM ADIOL, 2 nM ADIOL,
IgM TAM, 10gM TAM, I LM TAM+2nM ADIOL or IOtM
TAM + 2 nm ADIOL. The media were renewed on the fourth
day. On day 6, cells were counted and expressed as the percent-
age variation of the cell number in the control group. Each
column represents the mean ± s.e. ofeight experiments performed
in triplicate.
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Figure 3 Effect of increasing concentrations of ADIOL and
DHT on the E2-induced proliferation of cells. Cells were seeded
at a density of about 2 x I04cells per dish and cultured in a
medium supplemented with 10% steroid-stripped fetal calf serum.
One day after seeding, ADIOL or DHT was added to cell
cultures at the indicated concentrations in the presence of 10 nM
E2 or 1 nm E2. On day 6, cells were counted. Bars indicate the cell
count of steroid-free (control) and cultures to either I nm or
10 nm E2 was added. All values represent mean cell counts ± s.e.
of quadruplicate cultures. *, 10 nm E2 + ADIOL; A, I nM
E2 + ADIOL; A, 1 nM E2 + DHT.
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Figure 2 Effect of increasing concentrations of ADIOL (A) and
DHT (A) on the proliferaton of cells. Cells were seeded at a
density of about 2 x IO' cells per dish and cultured in a medium
supplemented with 10% steroid-stripped fetal calf serum. One
day after seeding, ADIOL or DHT was added at the indicated
concentrations. On day 6, cells were counted. Control cell counts
are indicated by a hatched bar. All values represent mean cell
counts ± s.e. of quadruplicate cultures.
while a very high DHT concentration (200 nM) stimulates
MCF-7 cell growth through an oestrogen receptor-mediated
mechanism (Zava & McGuire, 1978). The administration of
ADIOL (0.2-200 nM) together with E2 (Figure 3) inhibits
E2-induced cell proliferation: cell number per plate at day 6
of culture is lower (P<0.001) than after stimulation by E2
alone (Figure 1). The inhibitory effect of 2 nM ADIOL on
cell proliferation is maintained in increasing E2 concentra-
tions up to 10 nM (Figure 3). The administration of DHT
(0.2-200 nM) together with 1 nM E2 has an inhibitory effect
similar to that of ADIOL (Figure 3). Growth curves of E2
alone, E2 plus ADIOL and E2 plus DHT are presented in
Figure 4. At 2 x 10-4 cells cm-2 well seeding density, both
ADIOL and DHT affect log phase growth.
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Figure 4 Time course of the effect of E2 alone (O), E2 plus
ADIOL (A) and E2 plus DHT (A) on the proliferation of
MCF-7 cells. Cells were seeded at a density of about 2 x 104cells
per dish and cultured in a medium supplemented with 10%
steroid-stripped fetal calf serum (FCS-DCC). One day after
seeding, 1 nM E2 alone, I nM E2 plus 2 nm ADIOL and 1 nM E2
plus 2 nm DHT were added and cell number was determined at
the indicated times. Control cells (0) received FCS-DCC. All
values represent mean cell counts of triplicate cultures in which
s.e. was less than 8%.
Effect ofADIOL on tamoxifen-inhibited MCF-7 cellgrowth
In order to better understand the inhibitory influence of
ADIOL on cell growth, we estimated the ability of ADIOL
to affect the growth of MCF-7 cells in the presence of
increasing concentrations of tamoxifen. In our experimental
conditions (10% FCS) TAM alone inhibits cell growth only
at high concentrations (10 fLM) (Table I), in agreement with a
previous report (Chouvet et al., 1988). The administration of
2 nM ADIOL together with TAM results in a more marked
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Table I Effect of tamoxifen in the presence or absence of I nm E2
or 2 nM ADIOL on MCF-7 cell growth after a 6 day incubation
Cell growth (cells per well x 10-S)
No steroids + E2 I nM + ADIOL 2nM
FCS-DCC 1.28 ± 0.13 3.54 + 0.32t 1.85 ± 0.19t
TAM 0.1 sM 1.25 0.14 1.49 0.16tt 1.38 0.14tt
TAM IllM 1.32±0.15 1.29±0.14 1.18±0.13**
TAM 10 JLM 0.80± 0.06t 0.77± 0.06t 0.68± 0.06*t
Each value represents the mean ± s.d. of four separate experiments
set up in triplicate. **P <0.05, *P <0.01 vs respective control
without steroid added. ttP <0.01, tP <0.001 vs FCS-DCC without
steroid added (paired data Student's t-test).
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inhibitory effect on cell proliferation: the cell number is lower
(P<0.01) in the presence of ADIOL plus TAM than in the
presence of TAM alone, even at a TAM concentration that
completely counteracts the E2 stimulatory effect (Table I and
Figure 1). In preliminary experiments we observed that, in
10% FCS steroid-stripped culture medium, 1 gM TAM com-
pletely counteracts the stimulatory effect of 1 nM E2 on cell
growth (Table I).
Effect ofADIOL on MCF-7 cellgrowth in the presence of
diethylstilboestrol (DES)
DES stimulation of MCF-7 cell growth is shown in Figure 5.
ADIOL at 2 nM was added together with DES at concentra-
tions of up to 100 nM. As expected, at DES concentrations
unable to influence cell proliferation, ADIOL induces a maxi-
mal 2-fold stimulation of cell proliferation, acting as
oestrogen. Conversely, the inhibitory effect of ADIOL
becomes evident at higher DES concentrations: the cell
number at day 6 of culture is lower in the presence of
DES + ADIOL than in the presence of DES alone. The effect
is maintained at maximally stimulating DES concentra-
tions.
Effect ofhydroxyflutamide (OH-FLU) on MCF-7 cell growth
The effects on cell growth of the antiandrogen OH-FLU,
which binds to ARs with a much greater affinity than
flutamide (Neri et al., 1972; Simard et al., 1986; Brogden &
Chrisp, 1991), are shown in Figure 6. The dose-response
curve shows that OH-FLU completely reverses the inhibitory
effect of ADIOL on E2-induced cell growth, suggesting that
this effect is mediated by AR. Figure 6 also shows that
OH-FLU at high concentration, alone or in combination
with either E2 or ADIOL, exerts a negligible antiproliferative
effect. This effect of OH-FLU on breast cancer cell growth
has been reported previously (Di Monaco et al., 1993).
Discussion
We have previously reported that adrenal androgens are able
to decrease the growth of dimethylbenz[a]anthracene
(DMBA)-induced mammary tumours in adult rats (Boccuzzi
et al., 1992b) as well as to inhibit in vitro the oestrogen-
dependent proliferation of MCF-7 breast cancer cells (Boc-
cuzzi et al., 1992a). In this paper the mechanism of the
antiproliferative action of ADIOL on the oestradiol-induced
growth of breast cancer cells was investigated. ADIOL bind-
ing to ERs (Poortman et al., 1975; Kreitman & Bayard,
1979; Adams et al., 1980) has been suggested to account for
its antioestrogenic action: it might displace E2 from ERs,
antagonising the stronger E2 stimulatory activity (Thjissen et
al., 1975; Garcia & Rochefort, 1978; Nicholson et al., 1978).
The results show that the antiproliferative effect of ADIOL
at nanomolar concentrations is unaffected by increasing
amounts of either E2 or DES. Moreover, the inhibitory
effects of ADIOL are additive to the antiproliferative activity
of TAM alone, even at TAM concentrations that fully inhibit
the stimulatory effect of E2 on cell growth. Taken together,
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Figure 5 Effects of ADIOL on DES-induced growth of MCF-7
cells. Cells were seeded at a density of about 2 x 104 cells per dish
and cultured in a medium supplemented with 10% steroid-
stripped fetal calf serum. One day after seeding, DES was added
to cell cultures at the indicated concentrations in the absence (0)
or in the presence (U) of 2 nM ADIOL. On day six, cells were
counted. All values represent mean cell counts ± s.e. of quadrup-
licate cultures.
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Figure 6 Effect of increasing concentrations ofhydroxyflutamide
on the cell growth. Cells were seeded at a density of about
2 x 1O4cells per dish and cultured in a medium supplemented
with 10% steroid-stripped fetal calf serum. One day after seeding,
OH-FLU was added to cell cultures at the indicated concentra-
tions in the absence (0, control) or in the presence of 1 nM E2
(O), 2 nM ADIOL (A) or 1 nM E2 plus 2 nM ADIOL (A). On
day 6, cells were counted. All values represent mean cell counts
s.e. of quadruplicate cultures.
these results exclude the competition of ADIOL with E2 at
the ER level.
It has been previously shown that classical androgens also
exert antiproliferative activity on human breast cancer;
inhibition is mediated by ARs, being specifically counteracted
by antiandrogens (Maclndoe & Etre, 1981; Poulin et al.,
1988, 1989). Here we show that both ADIOL and the full
androgen DHT inhibit E2-induced cell growth. ADIOL,
unlike DHT, is inhibitory only in the presence of oestradiol,
being stimulatory in its absence. Antiandrogens completely
block ADIOL antiproliferative activity, but do not modify its
stimulatory activity, which depends on ER.
In conclusion, ADIOL at concentrations similar to those
8
6
6"1.6
5
11038 G. BOCCUZZI et al.
found in human plasma can activate both ERs and ARs.
When ERs are blocked, ADIOL effects mediated by ARs
become evident. These data may have clinical relevance, since
opposing roles of ADIOL on breast cancer progression are
suspected, depending on the endocrine environment: in
premenopausal women ADIOL may partially counteract E2
stimulation, thus acting as anticarcinogenetic factor. On the
other hand, E2 withdrawal at menopause allows ADIOL to
activate ERs and to act as a stimulatory factor. These con-
clusions are in agreement with epidemiological studies (Bul-
brook et al., 1971; Wang et al., 1975; Segaloff et al., 1980;
Zumoff et al., 1981; Helzlsouer et al., 1992) and are sup-
ported by experimental data showing that adrenal androgens
can exert opposite effects on rat mammary tumours, depend-
ing on the oestrogenic environment (Boccuzzi et al.,
1992b).
It should also be emphasised that the inhibitory effect of
ADIOL is maintained in the presence of TAM. A similar
additive inhibitory action, via AR activation, has already
been shown for DHT (Poulin et al., 1988) and for fluoxy-
mesterone (Ingle et al., 1991). Although a large body of
experimental as well as clinical data shows that the anti-
tumour activity of TAM is due to ER-mediated blockade of
oestrogen action, TAM also displays several additional pro-
perties, independent of ERs, which are important in the
control of cellular proliferation (Huynh et al., 1993). Our
data suggest that antioestrogens might influence breast
cancer growth by an additional and indirect pathway: ER
blockade by tamoxifen might allow ADIOL and other andro-
gens from the adrenals and ovaries to exert antiproliferative
effects via ARs. The additive effect shown in vitro by ADIOL
and TAM may have clinical relevance. Aromatase inhibitors
such as 4-hydroxyandrostendione, which reduces the conver-
sion of adrenal androgens to oestradiol, are presently recom-
mended as an alternative to tamoxifen in breast cancer
therapy. Evidence of an additive effect of adrenal androgen
and antioestrogens might suggest the simultaneous admini-
stration of aromatase inhibitors and tamoxifen: aromatase
inhibitors could block the conversion of adrenal androgens,
allowing their direct inhibition of cell proliferation. The
inhibition mediated by AR could be obtained only if ERs are
simultaneously blocked by antioestrogens.
This work was supported by MURST funds.
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